Skip to main content
. 2021 Oct 24;19:339. doi: 10.1186/s12951-021-01085-y

Fig. 3.

Fig. 3

In vitro therapeutic efficacy of CLip-PC@CO-LC NPs. Dosage-dependent response of cell viability in A549 cells after treatment with DTX, CLip-PC@LC-DTX NPs, CLip-PC@LC-siPGAM1 NPs, CLip-PC@CO-LC NPs, or CLip-PC@CO-LC NPs (MMP-9) for a 24 h and b 48 h; data are represented as mean ± standard deviation (SD; n = 5). c Fluorescence-activated cell sorter analysis of apoptosis after annexin V-fluoresceine isothiocyanate/propidium iodide (FITC/PI) staining. d Percentages of apoptotic and necrotic cells were determined using Annexin V-PI; mean ± SD (n = 3). e Histograms showing the percentage of A549 cells in different phases of the cell cycle after a 48 h treatment with different DTX formulations. f S, G2/M, G1 phase distributions of various groups (results are shown as mean ± SD, n = 3)